EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer

Balducci, 2000, General guidelines for the management of older patients with cancer, Oncology, 14, 221

Gómez, 1998, Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity, J. Clin. Oncol., 16, 2352, 10.1200/JCO.1998.16.7.2352

Lyman, 2002, Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients, Curr. Opin. Hematol., 9, 207, 10.1097/00062752-200205000-00006

Repetto, 2002, A case for geriatric oncology, Lancet Oncol., 3, 289, 10.1016/S1470-2045(02)00730-1

Crawford, 2000, Suboptimal dosing in adjuvant breast cancer chemotherapy, Breast Cancer Res. Treat., 64, 66

Lyman, 2001, Clinical prediction models for febrile neutropenia and relative dose intensity in patients receiving adjuvant breast cancer chemotherapy, Proc. Am. Soc. Clin. Oncol., 20, 394A

Eppelbaum, 1988, Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma, Isr. J. Med. Sci., 24, 533

Kwak, 1990, Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis, J. Clin. Oncol., 8, 963, 10.1200/JCO.1990.8.6.963

Lepage, 1993, Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to the LNH-87 protocol. The GELA (Groupe d'Etude des Lymphomas de l'Adult), Ann. Oncol., 4, 651, 10.1093/oxfordjournals.annonc.a058619

Bonadonna, 1995, Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer, N. Engl. J. Cancer, 332, 901, 10.1056/NEJM199504063321401

Dees, 2000, A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer, Cancer Invest., 18, 521, 10.3109/07357900009012191

Chatta, 1994, Aging and marrow neutrophil reserves, J. Am. Geriatr. Soc., 42, 77, 10.1111/j.1532-5415.1994.tb06077.x

Ozer, 2000, Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines, J. Clin. Oncol., 18, 3558, 10.1200/JCO.2000.18.20.3558

Balducci, 2001, Patients aged ⩾70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy, J. Clin. Oncol., 19, 1583, 10.1200/JCO.2001.19.5.1583

Constenla, 2000, Docetaxel (TXT) monotherapy & G-CSF for advanced breast cancer (ABC) in elderly patients (EP), Proc. Am. Soc. Clin. Oncol., 19, 110a

Shogan, 2002, Pegfilgrastim shows safety and efficacy similar to filgrastim in elderly patients with breast cancer, Proc. Am. Soc. Clin. Oncol., 21, 66a

Doorduijn, 2002, Prophylactic granulocyte colony-stimulating factor (G-CSF) added to CHOP in the treatment of elderly patients with aggressive non-Hodgkin's lymphoma (NHL). Final results of a multicenter phase 3 study, Ann. Oncol., 13, 28

Bjorkholm, 1999, Randomized trial of r-metHu granulocyte colony-stimulating factor (G-CSF) as adjunct to CHOP or CNOP treatment of elderly patients with aggressive non-Hodgkin's lymphoma, Blood, 95, 599

Zinzani, 1997, Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma, Blood, 89, 3974

Pfreundschuh, 2002, 2-weekly CHOP (CHOP-14): the new standard regimen for patients with aggressive non-Hodgkin's lymphoma (NHL) >60 years of age, Ann. Oncol., 13, 27

Pronzato, 1998, High-dose intensity cyclophosphamide, epidoxorubicin, vincristine and prednisone by shortened intervals and granulocyte colony-stimulating factor in non-Hodgkin's lymphoma: a phase II study, Br. J. Cancer, 78, 777, 10.1038/bjc.1998.578

Gregory, 2000, 14 day CHOP in patients with aggressive non-Hodgkin's lymphoma (NHL): preliminary results, Proc. Am. Soc. Clin. Oncol., 19, 15a

Engelhard, 1994, Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin's lymphomas: results of a randomized double-blind placebo-controlled study with intensified COP-BLAM +/−rhGM-CSF, Ann. Oncol., 5, 123, 10.1093/annonc/5.suppl_2.S123

Kaku, 1993, Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) after chemotherapy in patients with non-Hodgkin's lymphoma; a placebo-controlled double blind phase III trial, Leuk. Lymphoma, 11, 229, 10.3109/10428199309087000

Langer, 1995, Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis, J. Clin. Oncol., 13, 1860, 10.1200/JCO.1995.13.8.1860

Eguchi, 1994, Efficacy of recombinant human granulocyte-macrophage colony-stimulating factor for chemotherapy-induced leukopenia in patients with non-small-cell lung cancer, Cancer Chemother. Pharmacol., 34, 37, 10.1007/BF00686109

Gordon, 1999, A phase I/II dose escalation study of carboplatin in the treatment of newly diagnosed patients with advanced ovarian cancer receiving paclitaxel, Am. J. Clin. Oncol., 22, 601, 10.1097/00000421-199912000-00011

Fanning, 1996, Prophylactic granulocyte colony-stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer, Gynecol. Oncol., 63, 323, 10.1006/gyno.1996.0330

Crawford, 1991, Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer, New Engl. J. Med., 325, 164, 10.1056/NEJM199107183250305

Trillet-Lenoir, 1993, Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy, Eur. J. Cancer, 29A, 319, 10.1016/0959-8049(93)90376-Q

Negoro, 1997, Dose-intensive chemotherapy in extensive-stage small-cell lung cancer, Cancer Chemother. Pharmacol., 40, S70, 10.1007/s002800051065

Gatzemeier, 2000, Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study, Am. J. Clin. Oncol., 23, 393, 10.1097/00000421-200008000-00017

Miles, 1994, Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer, J. Clin. Oncol., 12, 77, 10.1200/JCO.1994.12.1.77

Eguchi, 1994, A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with advanced small cell lung cancer, Eur. J. Cancer, 30A, 188, 10.1016/0959-8049(94)90085-X

Thatcher, 2000, J. Clin. Oncol., 18, 395, 10.1200/JCO.2000.18.2.395

Tjan-Heijnen, 2001, Dose-intensification of cyclophosphamide, doxorubicin and etoposide (CDE) chemotherapy does not improve survival in small cell lung cancer (SCLC): final results of a randomized phase III EORTC study, Proc. Am. Soc. Clin. Oncol., 20, 346a

Woll, 1995, Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer, J. Clin. Oncol., 13, 652, 10.1200/JCO.1995.13.3.652

Bunn, 1995, Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group, J. Clin. Oncol., 13, 1632, 10.1200/JCO.1995.13.7.1632

Hamm, 1994, Dose-ranging study of recombinant granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma, J. Clin. Oncol., 12, 2667, 10.1200/JCO.1994.12.12.2667

Steward, 1998, Effects of granulocyte-macrophage colony-stimulating factor and dose-intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients, J. Clin. Oncol., 16, 642, 10.1200/JCO.1998.16.2.642

Sculier, 2001, A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics, Br. J. Cancer, 85, 1444, 10.1054/bjoc.2001.2114

Kotake, 1999, Effect of recombinant human granulocyte colony stimulating factor (lenograstim) on chemotherapy induced neutropenia in patients with urothelial cancer, Int. J. Urol., 6, 61, 10.1046/j.1442-2042.1999.00624.x

Sternberg, 2001, J. Clin. Oncol., 19, 2638, 10.1200/JCO.2001.19.10.2638

Pronzato, 1997, Intensified M-VEC chemotherapy with G-CSF support as outpatient treatment for advanced bladder cancer, Anticancer Res.., 17, 2325

Lyman, 2002, Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy, Am. J. Med.., 112, 406, 10.1016/S0002-9343(02)01036-7

Loehrer, 1994, Escalated dosages of methotrexate, vinblastine, doxorubicine and cisplatin plus recombinant human granulocyte colony stimulating factor in advanced urothelial carcinoma, J. Clin. Oncol., 12, 483, 10.1200/JCO.1994.12.3.483